The following is a summary of “Patients with anti-PM/Scl-positive and idiopathic inflammatory myopathy resemble ...

A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic ...

Explore how tumor necrosis factor inhibitors (TNFis) may reduce cardiovascular risks in patients with inflammatory arthritis, ...

The following is a summary of “Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies ...

Idiopathic inflammatory myopathies (IIMs) are associated with autoantibodies against nuclear and cytoplasmic antigens. Myositis-specific autoantibodies (MSAs) are specific to patients with IIMs.

• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

The chronic inflammatory myopathies are idiopathic, meaning they have no known cause. They are thought to be autoimmune disorders, in which the body's white blood cells (that normally fight ...

Allogene Therapeutics Inc. surged over 42% last week amid a bullish analyst take on its latest immuno-oncology update and a ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.